Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VOS
|
|||
| Former ID |
DIB004201
|
|||
| Drug Name |
ETI-204
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anthrax [ICD-11: 1B97; ICD-9: 22] | Approved | [1] | |
| Company |
Elusys Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacillus anthracis Protective antigen (Anthrax PA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.